Dr. Sudhir Srivastava has been Chief of the Cancer Biomarkers Research Group since 2000. His efforts focus on molecular biology of malignancies, early malignancies, risk assessment, and informatics, providing leadership in the areas of molecular screening and early detection. He is one of the principal authors of the Bethesda Guidelines for diagnosing Hereditary non-polyposis colorectal cancer.
He received several national/international honors and awards and is a member of a number of scientific committees. In 1995, he was elected to the American Joint Committee on Cancer, which is responsible for developing staging criteria for cancers for worldwide use, and serves on the Executive Committee—he was the first Asian American and non-MD to do so. Under his leadership, AJCC accepted the inclusion of tumor markers in the staging guidelines for colorectal cancer. He received several NIH and NCI honors and awards, has initiated and chaired state-of-the-science national and international-level workshops and conferences, and was principal architect of the first Gordon Research Conference on New Frontiers in Cancer Detection and Diagnosis.
He initiated new areas of research (molecular signatures of infectious agents in cancer; micro-imaging in classifying preneoplastic lesions; nano-technology in Earlier Cancer Detection; Metabolomics and Glycomics Alliances with other NIH Institutes). He published more than 170 peer-reviewed papers and has edited four books. He is Editor-In-Chief for the journal Disease Biomarkers; led creation of the journal Cancer Biomarkers; was appointed to the editorial board of the journal Cancer Prevention Research; is a member of several scientific committees; founding member of HUPO; principal architect of NCI's Early Detection Research Network; and founding Editor and Board member for Journal of Proteomics & Bioinformatics. He has a PhD in biological science; MS in computer science; and MPH from the Johns Hopkins University.